Nepsone

Nepsone is a private, preclinical biotech founded in 2019 with a novel neuroimmunology hypothesis for dermatological diseases. The company is developing small molecule drugs aimed at correcting autonomic nervous system imbalances, specifically targeting neuropeptide pathways, as a new treatment paradigm for conditions like psoriasis. It is backed by a grant from Iceland's Technology Development Fund (Rannís) and led by a team with expertise in R&D, clinical development, and finance. Nepsone operates in a large, underserved market dominated by biologic therapies, positioning its oral small molecule approach as a potential disruptive alternative.

A neuroimmunology platform targeting imbalances in the autonomic nervous system and neuropeptide activity as the root cause of inflammatory skin diseases, leading to the development of small molecule modulators.

Nepsone competes in the highly competitive psoriasis market dominated by effective but expensive biologic drugs and newer oral agents like PDE4 and TYK2 inhibitors. Its differentiation hinges entirely on its novel neuro-immunological mechanism, which, if proven, would not be directly targeted by existing therapies, potentially carving out a unique niche.